Paragard IUD
The Paragard IUD MDL was centralized in December 2020 to coordinate claims that the copper intrauterine device, unlike hormonal IUDs marketed as a competing option, is prone to breaking or fracturing during removal, with fragments sometimes migrating within the body and requiring additional procedures — occasionally including surgery — to locate and remove. With 4,185 actions pending, this is a substantial, actively developing docket built around a device-defect and inadequate-warnings theory.
What distinguishes this docket's resolution-risk profile is that the core injury event — a device fracturing during a specific removal procedure — is typically well documented through the medical record of that removal, giving this litigation a more incident-based causation structure than a chronic-exposure drug tort where establishing the causal link to injury can be a more open scientific question. The central litigated issues instead concern design defect (whether the device's material and design made fracture during removal foreseeable and preventable) and failure to warn (whether patients and providers were adequately informed of the fracture risk and appropriate removal technique).
Because the underlying injury events are individually documented rather than dependent on a contested general-causation theory, this docket's bellwether and resolution dynamics tend to center on design-defect and warnings evidence common across the product line, even as damages remain individualized based on each claimant's specific retrieval complications. That combination — a relatively stable common-issue core with individualized damages — is a structural pattern that can support movement toward a comprehensive resolution once the common design-defect and warnings questions are sufficiently tested through bellwether litigation.
Criterica Intelligence tracks this distinction between incident-based causation dockets and cumulative-exposure or epidemiological-causation dockets as a meaningful structural factor in reading resolution-path likelihood, and surfaces it across the active MDL landscape alongside its other structural indicators.
It consolidates claims that the copper Paragard IUD is prone to breaking or fracturing during removal, with fragments sometimes migrating and requiring additional procedures to locate and remove, on design-defect and failure-to-warn theories.
Bellwether trials test the common design-defect and warnings evidence that applies across the product line, helping establish how courts and juries evaluate those shared theories before the remaining individualized claims are resolved.
It proceeds toward an individual trial, where the common design-defect and warnings record developed through bellwether litigation is likely to apply, alongside that specific claimant's documented retrieval-procedure facts.
The injury here stems from a discrete, documented event — a device fracture during removal — rather than years of cumulative exposure, which gives the litigation a more incident-based causation structure than many pharmaceutical mass torts.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.